Panelists:Philip L. Smith, PhD, Founder
PNPSmith Associates Consulting, Inc.
Joyce A. Lonergan, Founder
The Pine Cone Consulting Company, Inc.
Robert Hayes, Ph.D., Venture Leader, Centyrex
Johnson & Johnson Ventures
Robin Hwang, Executive Director, Head of Drug Delivery
Halozyme Therapeutics, Inc.
Nicholas C. Nicolaides,
President, Chief Executive Officer, Morphotek, Inc.
When you have antibodies in high concentration, it’s difficult in terms of penetration. The syringe-ability is very difficult. There are ways to try to ease the delivery of antibodies. There are quite a few device companies who are trying to develop delivery devices. One must balance flow rate, volume, viscosity, and needle gauge determine device types.
Therapeutic antibodies are continuing to expand. Scaffolds have a promise of increasing the range of applications. Delivery still has quite a bit of future improvement.
Combination product and regulatory hurdles: It’s not as difficult as it was, but now there are a few combination products that can be prescribed. There are many places you can clarify the regulatory pathway, and it’s not as difficult as it used to be.
Route administration: What role will devices play?
Product and indication specific. Antibodies developing for infectious disease. The development plan must to show the product is active. IV administration is this way. Once experienced in man, you can then demonstrate if it’s effect.
|
Share this article with your social network, just click below to share now!
|
|
|
No comments :
Post a Comment